Pharma

Principia, AbbVie walk away from 2017 partnership for inflammatory, autoimmune drugs

San Francisco-based Principia and partner AbbVie have elected to part ways on a collaboration they signed about two years ago, which handed the newly public biotech $15 million upfront.

Martin Babler

The drug developer, run by a troop of executives drawn from Roche, joined forces with AbbVie in June 2017 to develop oral immunoproteasome inhibitors for inflammatory and autoimmune disorders. Immunoproteasome is a family of proteasome — the cell’s protein recyclers — found abundantly in immune cells, which play a role in immune responses, affecting antigen presentation, T cell function and cytokine production.

The collaboration could have given Principia — which went public last year in an upsized $108 million IPO — up to $667.5 million in milestone payments, in addition to tiered royalty on sales. At the moment, the program is in advanced lead optimization (the stage that precedes preclinical testing).

AbbVie $ABBV decided the program was no longer a strategic fit, Principia chief Martin Babler said on Monday.

Principia $PRNB, which also counts Sanofi as partner, has a BTK inhibitor as its lead drug — PRN1008 — designed for autoimmune diseases, and is currently in a late-stage study for rare cases of a chronic skin condition called pemphigus.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,100+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Director Process Development
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->